Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6541
    +0.0017 (+0.27%)
     

  • OIL

    83.75
    +0.18 (+0.22%)
     

  • GOLD

    2,352.60
    +10.10 (+0.43%)
     

  • Bitcoin AUD

    97,854.53
    -1,141.43 (-1.15%)
     

  • CMC Crypto 200

    1,333.39
    -63.14 (-4.52%)
     

  • AUD/EUR

    0.6106
    +0.0033 (+0.54%)
     

  • AUD/NZD

    1.0993
    +0.0036 (+0.32%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,738.20
    +307.69 (+1.77%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,292.59
    +206.79 (+0.54%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant

Vir Biotechnology, Inc.
·1-min read

--Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET--

SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant.

To access the call via telephone, please dial (833) 727-9519 (North America) or (830) 213-7696 (International), conference ID: 9894016.

A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

ADVERTISEMENT

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.

CONTACT: Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Cara Miller VP, Corporate Communications cmiller@vir.bio +1-415-941-6746